Psicología de educativa

In this podcast series, DPHARM Director Tracey Kimball with Valerie Bowling, Executive Director of the Conference Forum, break down what to expect at DPHARM 2025. Part II of this podcast series covers the 16 Pharma from the Trenches track case studies.

★毎週土曜日、夜10：30に配信！ ★ 「#ドリームハート 」の番外編番組 「#茂木健一郎のポジティブ脳教室 」 ここでは リスナーの皆様から寄せられたお悩みやご質問に 茂木健一郎さんが #脳科学 的にお答えし「ポジティブな考え方」を伝授していきます！ 今夜は 山口県の「ラジオネーム けんちゃん」さんからのメッセージ。 =========================================== 茂木さん こんばんは。 自分は情報を集めるのが 好きですが 集めすぎて 以前はパニックになっていました。 今は 大分うまくなりましたが たまに 疲れ果てます。 これも経験を積み重ねないと 駄目なんですかね？ 忌憚ないアドバイス、宜しくお願いいたします。 =========================================== 今週は こちらのご質問にお答えしていきます。 茂木さんに聞いて欲しい疑問・質問、お悩みやご相談など… 全てのメッセージは 毎週土曜日の夜10時から 全国38局で放送している 【#DreamHeart

科研喵使用ai读文献，祝你效率百倍，访问labcat.com.cn下载。本期关注发表在影响因子高达21.7的《Journal of the American College of Cardiology》上的重要论文"Fibrinolytic Therapy for Thromboembolic Diseases: Approved Indications and Future Directions"。这项全面综述探讨了纤维蛋白溶解疗法在血栓栓塞性疾病中的应用历程与未来发展。研究详细介绍了从1933年链激酶发现至今，各种纤维蛋白溶解剂的演变，包括阿替普酶及其改良型替奈普酶和瑞替普酶。文章重点分析了这些药物在ST段抬高型心肌梗死、急性缺血性卒中、肺栓塞等疾病中的治疗价值，同时强调了出血风险的平衡。研究还探讨了导管导向纤维蛋白溶解在中低风险血栓疾病中的应用前景，为临床医生提供了宝贵的治疗参考。

Join Jim as he hits the road with NGBiOnTheRoad, capturing exclusive conversations with trailblazers at BIO2025 in Boston.In this episode, Jim sits down with Nick Green, President & CEO of Avid Bioservices and former executive at Therapure Biopharma, for a candid group conversation that spans leadership, loyalty, and life after selling a company. Longtime colleague Vern Solomon of Environmental Systems Corporation joins in, sharing reflections on cleanroom builds, team culture, and why

Join Jim as he hits the road with NGBiOnTheRoad, capturing exclusive conversations with trailblazers at BIO2025 in Boston.In this episode, Jim reconnects—quite literally—with Brian Tennant, Scientific Director at   @GSK ​Canada, who he happened to sit behind on the flight to Boston. They chat about GSK's presence at BIO, Brian’s dual role bridging academic research and health policy, and how his coast-to-coast perspective from Victoria, BC, helps inform GSK’s national strategy. From

Join Jim as he hits the road with NGBiOnTheRoad, capturing exclusive conversations with trailblazers at BIO2025 in Boston.In this episode, Jim connects with Masha Ivan Kovic, founder of Mobile Consultants—a Quebec-based engineering firm supporting GMP pharmaceutical and biotech manufacturers. With deep expertise in process engineering and computerized systems, Masha shares insights on scaling support for clients of all sizes, the importance of partnerships, and what she's hoping to discover

Join Jim as he hits the road with NGBiOnTheRoad, capturing exclusive conversations with trailblazers at BIO2025 in Boston.In this episode, Jim sits down with Stephanie Schlifter from the @cityofbarrie to talk about why the city is planting its flag at BIO. Stephanie shares how Barrie is positioning itself as the next destination for life sciences companies seeking talent, space, and connectivity just north of the GTA. From investment attraction to entrepreneurial support, she unpacks how

Join Jim as he hits the road with NGBiOnTheRoad, capturing exclusive conversations with trailblazers at BIO2025 in Boston.In this episode, Jim reconnects with Mark Taylor, who leads commercialization at University Health Network (UHN). Mark shares his mission to transform how Canadian institutions bring research to market and unveils Canada Leads—a bold new UHN initiative aiming to recruit 100 post-docs from around the world. He also discusses how UHN is partnering with industry to drive

Join Jim as he hits the road with NGBiOnTheRoad, capturing exclusive conversations with trailblazers at BIO2025 in Boston.In this episode, Jim sits down with Stilian Nikolow, Vice President of Sales and Marketing of Vffice Inc., based in St. Hubert, Quebec. Stilian shares how Vffice is helping early-stage and established life sciences companies streamline their preclinical and clinical operations with enterprise software and productivity tools. As part of the Invest Québec delegation,

Join Jim as he hits the road with NGBiOnTheRoad, capturing exclusive conversations with trailblazers at BIO2025 in Boston.In this episode, Jim sits down with Andrea Horwath, Mayor of the  @InsideCityofHamilton ​, to talk about why Hamilton is becoming one of Canada’s most exciting life sciences hubs. From world-class research institutions and McMaster Innovation Park to a robust manufacturing legacy and growing biotech success stories like Fusion Pharmaceuticals and OmniaBio, Mayor Horwath

Join Jim as he hits the road with NGBiOnTheRoad, capturing exclusive conversations with trailblazers at BIO2025 in Boston.In this episode, Jason Field, President & CEO of  @LifeSciencesON ​, reflects on Ontario’s long-standing presence at BIO and the province’s evolving strategy to showcase its innovation ecosystem on the world stage. From government partnerships to university accelerators, Jason shares how collaboration has grown—and why events like BIO are critical for telling the

Join Jim as he hits the road with NGBiOnTheRoad, capturing exclusive conversations with trailblazers at BIO2025 in Boston.In this episode, Martin Bohl from the  @CityofBramptonYouTube ​ shares how the municipality is actively shaping its life sciences strategy through infrastructure, innovation, and investment. From a brand-new medical school—the first in Canada in over 100 years—to a growing base of major health corporates like Dynacare and Boston Scientific, Martin lays out Brampton’s

Join Jim as he hits the road with NGBiOnTheRoad, capturing exclusive conversations with trailblazers at BIO2025 in Boston.In this kickoff episode of NGBiOnTheRoad, host Jim Wilson sits down with Vern Solomon, founder of Environmental Systems Corporation (ESC), to talk about cleanroom innovation, Canada’s life sciences ecosystem, and the value of connecting with Canadian companies at BIO.Recorded live on-site, this conversation is part of our commitment to spotlighting the people driving

科研喵使用ai读文献，祝你效率百倍，访问labcat.com.cn下载。本期关注最新研究"Artificial Intelligence and Novel Trial Designs for Acute Ischemic Stroke: Opportunities and Challenges"，发表于Stroke期刊(影响因子7.8)。这项重要研讨探讨了AI和创新试验设计在急性缺血性卒中治疗中的潜力与挑战。研究发现，AI已在卒中影像中发挥关键作用，未来将在临床护理和研究试验中产生更大影响。研究强调"人类在回路"的重要性，以及平台试验和务实、以患者为中心的设计如何加速新疗法开发。这些工具有望彻底改变卒中临床试验，但需充分理解其优势和局限性，以推动更有效的卒中治疗策略。

科研喵使用AI读文献，祝你效率百倍，访问labcat.com.cn下载。今天我们关注发表在《Stroke》(IF:7.8)上的重要研究"Artificial Intelligence and Novel Trial Designs for Acute Ischemic Stroke: Opportunities and Challenges"。这项由卒中治疗学术产业圆桌会议组织的研究探讨了AI和创新临床试验设计在急性卒中领域的应用前景与挑战。研究发现，AI在影像学治疗中已发挥重要作用，未来几年将在临床护理和临床试验中产生更大影响。研究强调，高质量训练数据和"人工循环"元素对AI成功至关重要。同时，平台试验通过共享对照提高效率，而务实和以患者为中心的试验设计将加速新疗法的开发。这些创新工具有望彻底改变卒中治疗的未来！

科研喵使用ai读文献，祝你效率百倍，访问labcat.com.cn下载。今天我们关注发表在《Annals of neurology》(影响因子8.1)上的重要研究"Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large-Scale, Multi-Cohort Proteomic Study"。这项突破性研究通过大规模蛋白质组学分析，在ALS患者血浆中鉴定出329种显著差异表达的蛋白质，其中PDLIM3、TNNT2和MYL11大幅升高，而ANTXR2和ART3显著降低。更令人振奋的是，这些生物标志物不仅可用于ALS诊断，还能反映疾病进展，并有望成为评估治疗效果的重要工具。研究首次证实了肌肉作为ALS生物标志物的主要来源，为开发新型治疗策略提供了关键方向。

科研喵使用ai读文献，祝你效率百倍，访问labcat.com.cn下载。今天我们关注一篇发表在《Trends in pharmacological sciences》(影响因子13.9)上的重要研究，题为"Reprogramming SUMO-primed ubiquitylation: opportunities in oncology and neurology"。这项研究探讨了小泛素相关修饰(SUMO)靶向泛素连接酶(StUbLs)在疾病治疗中的潜力。研究人员发现，像三氧化二砷和氟维司群这样的抗癌药物能够利用SUMO化-泛素级联反应来失活致癌蛋白PML-RARα和雌激素受体α。更令人兴奋的是，新型 proximity-inducing 技术可将聚集蛋白招募到StUbL系统中，有望减轻神经毒性包涵物的形成。这一突破为肿瘤学和神经疾病领域开辟了全新的治疗途径，通过重新编程SUMO-StUbL信号通路，我们可能开发出针对更广泛疾病相关蛋白的靶向疗法。

Movement-sensing neurons that target the striatum influence a mouse’s choice of action by favoring routine.

👉 Para receber diretamente os áudios no seu celular, entre para o grupo: 🔗 https://site.vedanta.com.br/lead/cast-dz Saiba mais sobre esse conhecimento em: https://www.instagram.com/vedanta.soma